In this section, we are regularly sharing relevant information on patient-focused drug development.
PREFER’s patient input to decision making under evaluation by EMA and EUnetHTA. At Clinigma®, we are always happy to follow the development of projects promoting patient engagement...Read More
Have you considered improving the feedback from investigators and study nurses in your clinical trials?
The importance of interviewing investigators and study nurses. Not only is it relevant to interview the patients participating in clinical trials – it can also be highly valuable to…Read More
Screening and exit interviews are particularly beneficial to inform the development of drugs for rare diseases. Patient interviews can be helpful to obtain direct patient feedback regarding…Read More
Interviewing patients can help you in choosing the most relevant patient-reported outcome measures to apply in your clinical trials. Patient-reported outcome measures (PROMs) are frequently applied…Read More
Can you set a strong marketing strategy without hearing what users think about your investigational drug?
Get a clearer picture of your investigational drug prior to market launch. Interestingly, the pharmaceutical industry has remained one of the few industries where direct user feedback is not…Read More
EMA wants to strengthen the collaboration with HTAs to reinforce patient relevance in evidence generation
Highlights on EMA’s focus to advance patient-centred access to medicines in partnership with healthcare systems. In EMA’s Regulatory Science Strategy to 2025, the EMA presents...Read More